InflaRx NV (MEX:IFRXN) Short Percentage of Float

Name: InflaRx NV (IFRXN) — Historical Annual & Quarterly Data
Creator: GuruFocus
License: https://www.gurufocus.com/terms-of-service.php

What is InflaRx NV Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:IFRXN vs IRD, NAUT, RGNX: Short Percentage of Float Comparison

For the Biotechnology subindustry, InflaRx NV's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Short Percentage of Float falls into.

Save Embed

30GF Score

InflaRx NV MEX:IFRXN

Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InflaRx NV Business Description

Industry Healthcare Biotechnology

Comparable Companies IRD NAUT RGNX LRMR GLSI NMRA PBYI PALI IVVD RCKT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges IFRX:USA IF0:Germany

Address Winzerlaer Strasse 2, Jena, DEU, 07745

Website https://www.inflarx.de

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

30GF Score

Get the complete analysis for MEX:IFRXN

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN22.00

Price

View MEX:IFRXN Analysis

See Short Percentage of Float data for all stocks →